Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East

Table 1

Demographics and baseline disease characteristics.

	Tocilizumab
Patient characteristics
Sex, (%)
Female	78 (82.1)
Male	17 (17.9)
Race, (%)
White	69 (72.6)
Black	3 (3.2)
Other	23 (24.2)
Smokers, (%)	4 (4.2)
Age, years, mean (SD)	44.9 (13.7)
BMI, kg/m^2, mean (SD)	28.1 (5.4)
Disease characteristics
DAS28, mean (median [range])	6.1 (5.8 [3.4, 8.8])
Tender joint count, mean	13.28
Swollen joint count, mean	8.6
HAQ-DI, mean (SD)	1.6 (0.6)
CRP, mg/L, mean (SD)	26.9 (34.4)
ESR, mm/h, mean (SD)	45.3 (29.2)
Concomitant medication used by >10%, (%)
Immunosuppressants	86 (90.5)
Methotrexate	83 (87.4)
Prednisolone	47 (49.5)
Methylprednisolone	6 (6.3)
Prednisone	7 (7.4)
aTNF agent (etanercept or adalimumab)	5 (5.3)
Antianemia preparations	65 (68.4)
Anti-inflammatory and antirheumatic products	50 (52.6)
Vasoprotectives	46 (48.4)
Antiprotozoals	37 (38.9)
Mineral supplements	35 (36.8)
Vitamins	30 (31.6)
Antidiarrheals, intestinal anti-inflammatory/anti-infective agents	29 (30.5)
Drugs for acid-related disorders	27 (28.4)
Lipid-modifying agents	21 (22.1)
Drugs for treatment of bone diseases	14 (14.7)
Agents acting on the renin-angiotensin system	12 (12.6)
Drugs used in diabetes	11 (11.6)

BMI, body mass index; CRP, C-reactive protein; DAS28, Disease Activity Score based on 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; SD, standard deviation.